Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up

作者：Clatworthy Menna R^*; Friend Peter J; Calne Roy Y; Rebello Perpetua R U; Hale Geoffrey; Waldmann Herman; Watson Christopher J E

来源：Transplantation, 2009, 87(7): 1092-1095.

DOI：10.1097/TP.0b013e31819d3353

• Renal transplantation
• Acute rejection
• Alemtuzumab

Background. Alemtuzumab (MabCampath, Campath-1H) is a lymphocyte-depleting monoclonal antibody increasingly used in renal transplantation. This article reports the long-term follow-up data from the first series of patients treated with alemtuzumab for biopsy-proven acute rejection (BPAR).
Methods. Fifteen patients were identified who had received alemtuzumab for BPAR between November 1991 and June 1994. Patient and allograft survival were compared with a control group consisting of 25 patients with BPAR from the same era treated with intravenous methyl prednisolone, and with a contemporaneous UK renal transplant cohort.
Results. All rejection episodes responded to treatment with alemtuzumab but there was an excess of early infection-associated death in this group. Long-term transplant survival was similar in both groups as was allograft mean creatinine concentration at 10 years was 143 mu mol/L in alemtuzumab cohort and 183 Lxmol/L in control cohort, P=0.06). There was no excess incidence of malignancy or cytomegalovirus infection in this prolonged follow-up period.

• 出版日期2009-4-15
• 单位河北医科大学